Correction to: Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans, by Ellsworth JL, O'Callaghan M, Rubin H, and Seymour A.

Abstract

Human Gene Therapy Clinical DevelopmentVol. 29, No. 2 CorrectionFree AccessCorrection to: Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans, by Ellsworth JL, O'Callaghan M, Rubin H, and Seymour A.Hum Gene Ther Clin Devel 2017;29(1):60–67. DOI: 10.1089/humc.2017.239is erratum ofLow Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in HumansPublished Online:1 Jun 2018https://doi.org/10.1089/humc.2017.239.correxAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In the March 2018 issue of Human Gene Therapy Clinical Development (vol. 29, no. 1, pages 60–67), in the article entitled, Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans by J.L. Ellsworth et al., there was an error in the Materials and Methods section, under NAb analyses (page 61).The following sentence was written as:Since mouse serum in the presence of AAV activates β-galactosidase activity in the Huh7 cell assay in a dose-dependent manner (up to 15- to 2-fold at a 1/5 serum dilution), a 50% inhibition of cellular transduction at a 1/16 dilution of serum was used as cutoff for seropositivity for each AAV to minimize the number of false-positives.It should have read:Since mouse serum in the presence of AAV activates β-galactosidase activity in the Huh7 cell assay in a dose-dependent manner (up to 15- to 20-fold at a 1/5 serum dilution), a 50% inhibition of cellular transduction at a 1/16 dilution of serum was used as cutoff for seropositivity for each AAV to minimize the number of false-positives.The online version of the article has been corrected to reflect this change. The authors wish to apologize for the error.FiguresReferencesRelatedDetailsRelated articlesLow Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans1 Mar 2018Human Gene Therapy Clinical Development Volume 29Issue 2Jun 2018 InformationCopyright 2018, Mary Ann Liebert, Inc.To cite this article:Correction to: Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans, by Ellsworth JL, O'Callaghan M, Rubin H, and Seymour A..Human Gene Therapy Clinical Development.Jun 2018.113-113.http://doi.org/10.1089/humc.2017.239.correxPublished in Volume: 29 Issue 2: June 1, 2018Online Ahead of Print:May 30, 2018PDF download